Eye disease Clinical Trials

93 recruitingLast updated: July 25, 2026

There are 93 actively recruiting eye disease clinical trials across 41 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4, Early Phase 1. Top locations include Bethesda, Maryland, United States, Memphis, Tennessee, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Eye disease Trials at a Glance

93 actively recruiting trials for eye disease are listed on ClinicalTrialsFinder across 6 cities in 41 countries. The largest study group is Not Applicable with 22 trials, with the heaviest enrollment activity in Bethesda, Memphis, and Houston. Lead sponsors running eye disease studies include National Eye Institute (NEI), Laboratoires Thea, and Amgen.

Browse eye disease trials by phase

Treatments under study

About Eye disease Clinical Trials

Looking for clinical trials for Eye disease? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Eye disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Eye disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 93 trials

Recruiting

Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions

genetic eye disease
National Eye Institute (NEI)2,000 enrolled1 locationNCT02077894
Recruiting

Natural History, Pathogenesis, and Outcome of Ocular Disorders

Eye disease
National Eye Institute (NEI)1,000 enrolled1 locationNCT02821767
Recruiting
Phase 1

A Study of IBI3031 in Participants With Thyroid Eye Disease

Thyroid Eye Disease
Innovent Biologics (Suzhou) Co. Ltd.66 enrolled1 locationNCT07622368
Recruiting
Phase 1Phase 2

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

Thyroid Eye Disease
Amgen88 enrolled44 locationsNCT06401044
Recruiting

Clinical and Molecular Studies in Families With Inherited Eye Disease

Inherited Eye Disease
National Eye Institute (NEI)5,000 enrolled10 locationsNCT02771236
Recruiting
Phase 2Phase 3

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease

Dry Eye Disease (DED)
Oculis160 enrolled14 locationsNCT07548632
Recruiting
Phase 2

Dose-Finding Study of HUC1-394 in Participants With Dry Eye Disease

Dry Eye Disease (DED)
Huons Co., Ltd.150 enrolled1 locationNCT07656688
Recruiting

Screening for Research Participants

Eye Diseases
National Eye Institute (NEI)10,000 enrolled1 locationNCT00655096
Recruiting
Phase 2

An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease

Thyroid Eye Disease
Amgen30 enrolled6 locationsNCT07438405
Recruiting
Phase 3

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

Sensation DisordersLeber Congenital AmaurosisRetinal Disease+7 more
Laboratoires Thea32 enrolled17 locationsNCT06891443
Recruiting
Phase 4

Randomized Single Center Study to Evaluate Tolerability, Symptoms, and Visual Functional Outcomes With the Use of OTC Lubricating Eye Drops in Subjects With Dry Eye Disease

Dry Eye Disease (DED)
Andover Research Eye Institute60 enrolled1 locationNCT07676084
Recruiting
Phase 2

An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

Dry Eye Disease (DED)
Dompé Farmaceutici S.p.A417 enrolled24 locationsNCT07503886
Recruiting
Phase 4

A Multicenter, Open-Label Study to Evaluate Perioperative Treatment of Dry Eye With Miebo® in Subjects Undergoing LASIK

Dry Eye Disease (DED)Dry Eye Syndrome (DES)
Vance Thompson Vision100 enrolled4 locationsNCT07650708
Recruiting
Phase 2

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

deaf-blindRetinitis pigmentosa (RP)Retinal Disease+4 more
Laboratoires Thea81 enrolled28 locationsNCT06627179
Recruiting

Adaptive Optics Retinal Imaging

Healthy VolunteersEye Diseases
National Eye Institute (NEI)1,000 enrolled1 locationNCT02317328
Recruiting
Not Applicable

Evaluation of Tears Naturale® Free and Tears Naturale® II Lubricant Eye Drops

Dry-Eye Disease
Alcon Research120 enrolled6 locationsNCT07540884
Recruiting

The Proactive Ophthalmic Examination Cohort

Eye DiseasesVision Impairment
Zhongshan Ophthalmic Center, Sun Yat-sen University5,000 enrolled1 locationNCT05851287
Recruiting

Genetics of Inherited Eye Disease

genetic eye disease
National Eye Institute (NEI)1,500 enrolled1 locationNCT02471287
Recruiting
Not Applicable

Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease

Dry-Eye Disease
TRB Chemedica International SA80 enrolled2 locationsNCT05865379
Recruiting
Not Applicable

Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease

Dry-Eye Disease
TRB Chemedica International SA80 enrolled5 locationsNCT05865457